BCAL DiagnosticsASX:BDX -3.70% PB Ratio is 11.14 as of Jun. 26, 2026. The stock has 3 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 89.8% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), BCAL Diagnostics's share price is A$0.078. BCAL Diagnostics's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.01. Hence, BCAL Diagnostics's PB Ratio of today is 11.14.
The historical rank and industry rank for BCAL Diagnostics's PB Ratio or its related term are showing as below:
ASX:BDX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 11.86
Current: 11.14
During the past 4 years, BCAL Diagnostics's highest PB Ratio was 11.86. The lowest was 0.00. And the median was 0.00.
ASX:BDX's PB Ratio is ranked worse than 89.8% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs ASX:BDX: 11.14
During the past 12 months, BCAL Diagnostics's average Book Value Per Share Growth Rate was -72.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.20% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of BCAL Diagnostics was -28.20% per year. The lowest was -28.20% per year. And the median was -28.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BCAL Diagnostics PB Ratio Related Terms
BCAL Diagnostics PB Ratio Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BCAL Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's PB Ratio distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BCAL Diagnostics (ASX:BDX) has a PB Ratio of 11.14 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #176 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 89.8%.
Is BCAL Diagnostics' PB Ratio too high?
BCAL Diagnostics' current PB Ratio is 11.14. The Medical Diagnostics & Research industry median PB Ratio is 2.05. BCAL Diagnostics' value of 11.14 is 443.4% above this industry median. Based on the distribution chart, BCAL Diagnostics ranks #176 out of 196 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #176 out of 196 companies for PB Ratio. This places BCAL Diagnostics in the lower half of its industry. The industry median PB Ratio is 2.05. BCAL Diagnostics' value of 11.14 is 443.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BCAL Diagnostics's current PB Ratio of 11.14 is 443.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current PB Ratio is 11.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current PB Ratio of 11.14. The current PB Ratio is 11.14 and 443.4% above the Medical Diagnostics & Research industry median of 2.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current PB Ratio is 11.14 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 